A Novel MICB-Targeting CAR-NK Cells for the Treatment of Pancreatic Cancer
Open Access
- 3 January 2026
- journal article
- research article
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 27 (1) , 500
Abstract
MICB-targeting CAR-NK (chimeric antigen receptor-modified natural killer cells) therapy may serve as off-the-shelf immunotherapy. We designed soluble Anti-MICB-scFv blocks tumor immune evasion targeting the MICB antigen, thereby enhancing CAR-NK cytotoxicity while reactivating endogenous immune attacks against malignancies. The Anti-MICB-CAR includes two Anti-MICB-scFv connected by an F2A linker, the CD8 hinge and transmembrane domain, the 4-1BB co-stimulatory domain, the CD3ζ activation domain, and IL-15. The expression efficiency of Anti-MICB-CAR in NK cells was investigated by flow cytometry; ELISA demonstrated that Anti-MICB-CAR-NK secreted free Anti-MICB-scFv and detected IL-15 secretion. Flow cytometry and CCK8 were utilized to study Anti-MICB-CAR-NK on tumor cell viability. The PANC-1 xenograft model was established in order to elucidate the anti-tumor effects of Anti-MICB-CAR-NK in vivo. In vitro investigations have demonstrated that the treatment of tumor cells with Anti-MICB-CAR-NK supernatant + NK cells or Anti-MICB-CAR-NK cells not only significantly increased the cytotoxic activity of tumor cells, but also secreted and produced higher levels of IL-15, IFN-γ, TNF-α, perforin, and granzyme B compared with NK cells. Anti-MICB-CAR-NK cells exhibit strong cytotoxic activity against tumor cells with high MICB expression. In vivo, Anti-MICB-CAR-NK cells exhibited a substantial inhibitory effect on tumor growth. The IHC results reveal that Anti-MICB-CAR-NK cells show a more pronounced ability to infiltrate the tumor. We demonstrated the successful expression of Anti-MICB-CAR in NK cells, which enhances the anti-tumor activity of NK cells both in vitro and in vivo. This stress ligand-targeting approach provides a promising strategy for solid tumors.Keywords
Funding Information
- Nuclear (Shanghai) Pharmaceutical Technology Co., Ltd.
- the Science and Technology Commission of Shanghai Municipality, China (19411951100)
This publication has 47 references indexed in Scilit:
- CAR-T therapy in solid tumorsCancer Cell, 2025
- An epitope-directed mRNA vaccine inhibits tumor metastasis through the blockade of MICA/B α1/2 sheddingCell Reports Medicine, 2025
- Natural killer cells in cancer immunotherapyMedcomm, 2024
- A novel MICA/B-targeted chimeric antigen receptor augments the cytotoxicity of NK cells against tumor cellsBiochemical and Biophysical Research Communications, 2024
- Molecular mechanisms of snoRNA-IL-15 crosstalk in adipocyte lipolysis and NK cell rejuvenationCell Metabolism, 2023
- A chimeric antigen receptor uniquely recognizing MICA/B stress proteins provides an effective approach to target solid tumorsMed, 2023
- Harnessing IL-15 signaling to potentiate NK cell-mediated cancer immunotherapyTrends in Immunology, 2022
- CAR-NK cells: A promising cellular immunotherapy for cancerEBioMedicine, 2020
- Mechanisms of natural killer cell-mediated cellular cytotoxicityJournal of Leukocyte Biology, 2019
- Population study of allelic diversity in the human MHC class I-related MIC-A geneImmunogenetics, 1999